Lantheus Holdings shares rise 1.79% premarket after announcing a $400 million share repurchase program.

Lantheus Holdings, Inc. rose 1.79% in premarket trading, with the company announcing a share repurchase program of up to $400 million, valid until December 31, 2027. Additionally, the FDA accepted a New Drug Application for a new formulation of its F 18 PSMA imaging agent, with an action date goal of March 6, 2026. This new formulation is expected to increase batch size by ~50%, allowing Lantheus to serve more patients while maintaining high standards.